Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Animal Vaccines Market Research Report Information By Type (Porcine Vaccines, Poultry Vaccines, Livestock Vaccines, Companion Animal Vaccines, and Aquacultutre Vaccines), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Others), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032


ID: MRFR/HC/5718-CR | 169 Pages | Author: Kinjoll Dey| March 2022




Animal Vaccines Market Segmentation


Animal Vaccines Type Outlook (USD Billion, 2018-2030)




  • Porcine Vaccines




  • Poultry Vaccines




  • Livestock Vaccines




  • Companion Animal Vaccines




  • Aquacultutre Vaccines




Animal Vaccines Technology Outlook (USD Billion, 2018-2030)




  • Live Attenuated Vaccines




  • Inactivated Vaccines




  • Toxoid Vaccines




  • Recombinant Vaccines




  • Others




Animal Vaccines Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)




    • North America Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines










  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • North America Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • US Outlook (USD Billion, 2018-2030)




    • US Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • US Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • CANADA Outlook (USD Billion, 2018-2030)




    • CANADA Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • CANADA Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others







  • Europe Outlook (USD Billion, 2018-2030)




    • Europe Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines










  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Europe Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • Germany Outlook (USD Billion, 2018-2030)




    • Germany Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Germany Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • France Outlook (USD Billion, 2018-2030)




    • France Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • France Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • UK Outlook (USD Billion, 2018-2030)




    • UK Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • UK Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • ITALY Outlook (USD Billion, 2018-2030)




    • ITALY Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • ITALY Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • SPAIN Outlook (USD Billion, 2018-2030)




    • Spain Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Spain Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • Rest Of Europe Outlook (USD Billion, 2018-2030)




    • Rest Of Europe Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • REST OF EUROPE Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others







  • Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Asia-Pacific Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines










  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Asia-Pacific Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • China Outlook (USD Billion, 2018-2030)




    • China Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • China Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • Japan Outlook (USD Billion, 2018-2030)




    • Japan Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Japan Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • India Outlook (USD Billion, 2018-2030)




    • India Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • India Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • Australia Outlook (USD Billion, 2018-2030)




    • Australia Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Australia Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Rest of Asia-Pacific Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Rest of Asia-Pacific Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others







  • Rest of the World Outlook (USD Billion, 2018-2030)




    • Rest of the World Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines










  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Rest of the World Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • Middle East Outlook (USD Billion, 2018-2030)




    • Middle East Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Middle East Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • Africa Outlook (USD Billion, 2018-2030)




    • Africa Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Africa Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






    • Latin America Outlook (USD Billion, 2018-2030)




    • Latin America Animal Vaccines by Type




      • Porcine Vaccines




      • Poultry Vaccines









  • Livestock Vaccines




  • Companion Animal Vaccines








      • Aquacultutre Vaccines





    • Latin America Animal Vaccines by Technology




      • Live Attenuated Vaccines




      • Inactivated Vaccines




      • Toxoid Vaccines




      • Recombinant Vaccines




      • Others






Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY

2.2 RESEARCH OBJECTIVE

2.3 MARKET STRUCTURE

2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 RISING ZOONOTIC AND CHRONIC DISEASES IN ANIMALS

4.2.2 INCREASING EMPHASIS ON ANIMAL HEALTHCARE AND VACCINATION

4.2.3 INCREASED CONSUMPTION OF ANIMAL-BASED PRODUCTS

4.3 RESTRAINT

4.3.1 STRINGENT REGULATORY GUIDELINESANDHIGH STORAGE COSTSASSOCIATED WITH ANIMAL VACCINES

4.4 OPPORTUNITY

4.4.1 RISING INVESTMENTS IN VETERINARY HOSPITALSTO IMPROVE ANIMAL HEALTH

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 RESEARCH & DEVELOPMENT

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19ON THE GLOBAL ANIMAL VACCINES MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT OF COVID-19 ON ANIMAL DISEASE PREVENTION & CONTROL

5.3.3 IMPACT ON MARKET

6 GLOBAL ANIMAL VACCINES MARKET, BY TYPE

6.1 OVERVIEW

6.2 PORCINE VACCINES

6.3 POULTRY VACCINES

6.4 LIVESTOCK VACCINES

6.4.1 BOVINE VACCINES

6.4.2 SMALL RUMINANT VACCINES

6.5 COMPANION ANIMAL VACCINES

6.5.1 CANINE VACCINES

6.5.2 FELINE VACCINES

6.5.3 OTHERS

6.6 AQUACULTUTRE VACCINES

7 GLOBAL ANIMAL VACCINES MARKET, BY TECHNOLOGY

7.1 OVERVIEW

7.2 LIVE ATTENUATED VACCINES

7.3 INACTIVATED VACCINES

7.4 TOXOID VACCINES

7.5 RECOMBINANT VACCINES

7.6 OTHERS

8 GLOBAL ANIMAL VACCINES MARKET, BY REGION

8.1 OVERVIEW

8.2 AMERICAS

8.2.1 NORTH AMERICA

8.2.1.1 US

8.2.1.2 CANADA

8.2.2 SOUTH AMERICA

8.3 EUROPE

8.3.1 WESTERN EUROPE

8.3.1.1 FRANCE

8.3.1.2 GERMANY

8.3.1.3 UK

8.3.1.4 SPAIN

8.3.1.5 ITALY

8.3.1.6 REST OF WESTERN EUROPE

8.3.2 EASTERN EUROPE

8.4 ASIA-PACIFIC

8.4.1 JAPAN

8.4.2 CHINA

8.4.3 INDIA

8.4.4 AUSTRALIA

8.4.5 REPUBLIC OF KOREA

8.4.6 REST OF ASIA-PACIFIC

8.5 MIDDLE EAST & AFRICA

8.5.1 MIDDLE EAST

8.5.2 AFRICA

9 COMPETITIVE LANDSCAPE

9.1 COMPETITIVEOVERVIEW

9.2 MAJOR PLAYERS IN THE GLOBAL ANIMAL VACCINES MARKET

9.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL ANIMAL VACCINES MARKET

9.4 COMPETITIVE BENCHMARKING

9.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ANIMAL VACCINES MARKET

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES

9.6.2 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/INVESTMENTS

9.7 MAJOR PLAYERS FINANCIAL MATRIX

9.7.1 REVENUE OF MAJOR PLAYERS, 2020

9.7.2 R&D EXPENDITURE, 2020

10 COMPANY PROFILES

10.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 ZOETIS INC.

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS.

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 CEVA SANTÉ ANIMALE

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS/SERVICES OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 MERCK & CO., INC.

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 SWOT ANALYSIS

10.4.6 KEY STRATEGIES

10.5 ELANCO ANIMAL HEALTH INCORPORATED

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 SWOT ANALYSIS

10.5.6 KEY STRATEGIES

10.6 VIRBAC

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 PHIBRO ANIMAL HEALTH CORPORATION

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 KEY STRATEGIES

10.8 HIPRA

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 KEY STRATEGIES

10.9 BIOGÉNESIS BAGÓ S.A.

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

10.10 NEOGEN CORPORATION

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL: ANIMAL VACCINE MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 4 GLOBAL: ANIMAL VACCINE MARKET, FOR PORCINE VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 5 GLOBAL: ANIMAL VACCINE MARKET, FOR POULTRY VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 6 GLOBAL: ANIMAL VACCINE MARKET, FOR LIVESTOCK VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 7 GLOBAL: ANIMAL VACCINE MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 8 GLOBAL: ANIMAL VACCINE MARKET, FOR BOVINE VACCINES, 2023–2030 (USD MILLION)

TABLE 9 GLOBAL: ANIMAL VACCINE MARKET, FOR SMALL RUMINANT VACCINES, 2023–2030 (USD MILLION)

TABLE 10 GLOBAL: ANIMAL VACCINE MARKET, FOR COMPANION ANIMAL VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 11 GLOBAL: ANIMAL VACCINE MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 12 GLOBAL: ANIMAL VACCINE MARKET, FOR CANINE VACCINES, 2023–2030 (USD MILLION)

TABLE 13 GLOBAL: ANIMAL VACCINE MARKET, FOR FELINE VACCINES, 2023–2030 (USD MILLION)

TABLE 14 GLOBAL: ANIMAL VACCINE MARKET, FOR OTHERS, 2023–2030 (USD MILLION)

TABLE 15 GLOBAL: ANIMAL VACCINE MARKET, FOR AQUACULTUTRE VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 16 GLOBAL: ANIMAL VACCINE MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 17 GLOBAL: ANIMAL VACCINE MARKET, FOR LIVE ATTENUATED VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 18 GLOBAL: ANIMAL VACCINE MARKET, FOR INACTIVATED VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 19 GLOBAL: ANIMAL VACCINE MARKET, FOR TOXOID VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 20 GLOBAL: ANIMAL VACCINE MARKET, FOR RECOMBINANT VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 21 GLOBAL: ANIMAL VACCINE MARKET, FOR OTHER VACCINES, BY REGION, 2023–2030 (USD MILLION)

TABLE 22 GLOBAL: ANIMAL VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 23 AMERICAS: ANIMAL VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 24 AMERICAS: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 25 AMERICAS: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 26 AMERICAS: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 27 AMERICAS: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 28 NORTH AMERICA: ANIMAL VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 29 NORTH AMERICA: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 30 NORTH AMERICA: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 31 NORTH AMERICA: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 32 NORTH AMERICA: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 33 US: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 34 US: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 35 US: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 36 US: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 37 CANADA: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 38 CANADA: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 39 CANADA: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 40 CANADA: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 41 SOUTH AMERICA: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 42 SOUTH AMERICA: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 43 SOUTH AMERICA: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 44 SOUTH AMERICA: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 45 EUROPE: ANIMAL VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 46 EUROPE: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 47 EUROPE: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 48 EUROPE: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 49 EUROPE: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 50 WESTERN EUROPE: ANIMAL VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 51 WESTERN EUROPE: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 52 WESTERN EUROPE: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 53 WESTERN EUROPE: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 54 WESTERN EUROPE: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 55 FRANCE: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 56 FRANCE: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 57 FRANCE: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 58 FRANCE: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 59 GERMANY: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 60 GERMANY: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 61 GERMANY: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 62 GERMANY: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 63 UK: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 64 UK: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 65 UK: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 66 UK: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 67 SPAIN: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 68 SPAIN: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 69 SPAIN: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 70 SPAIN: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 71 ITALY: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 72 ITALY: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 73 ITALY: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 74 ITALY: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 75 REST OF WESTERN EUROPE: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 76 REST OF WESTERN EUROPE: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 77 REST OF WESTERN EUROPE: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 78 REST OF WESTERN EUROPE: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 79 EASTERN EUROPE: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 80 EASTERN EUROPE: ANIMAL VACCINES MARKET , BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 81 EASTERN EUROPE: ANIMAL VACCINES MARKET , BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 82 EASTERN EUROPE: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 83 ASIA-PACIFIC: ANIMAL VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 84 ASIA-PACIFIC: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 85 ASIA-PACIFIC: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 86 ASIA-PACIFIC: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 87 ASIA-PACIFIC: ANIMAL VACCINES MARKET, BYTECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 88 JAPAN: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 89 JAPAN: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 90 JAPAN: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 91 JAPAN: ANIMAL VACCINES MARKET, BYTECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 92 CHINA: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 93 CHINA: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 94 CHINA: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 95 CHINA: ANIMAL VACCINES MARKET, BYTECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 96 INDIA: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 97 INDIA: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 98 INDIA: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 99 INDIA: ANIMAL VACCINES MARKET, BYTECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 100 AUSTRALIA: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 101 AUSTRALIA: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 102 AUSTRALIA: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 103 AUSTRALIA: ANIMAL VACCINES MARKET, BYTECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 104 REPUBLIC OF KOREA: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 105 REPUBLIC OF KOREA: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 106 REPUBLIC OF KOREA: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 107 REPUBLIC OF KOREA: ANIMAL VACCINES MARKET, BYTECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 108 REST OF ASIA-PACIFIC: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 109 REST OF ASIA-PACIFIC: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 110 REST OF ASIA-PACIFIC: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 111 REST OF ASIA-PACIFIC: ANIMAL VACCINES MARKET, BYTECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 112 MIDDLE EAST & AFRICA: ANIMAL VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 113 MIDDLE EAST & AFRICA: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 114 MIDDLE EAST & AFRICA: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 115 MIDDLE EAST & AFRICA: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 116 MIDDLE EAST & AFRICA: ANIMAL VACCINES MARKET, BYTECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 117 MIDDLE EAST: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 118 MIDDLE EAST: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 119 MIDDLE EAST: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 120 MIDDLE EAST: ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 121 AFRICA: ANIMAL VACCINES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 122 AFRICA: ANIMAL VACCINES MARKET, BY LIVESTOCK VACCINES, 2023–2030 (USD MILLION)

TABLE 123 AFRICA: ANIMAL VACCINES MARKET, BY COMPANION ANIMAL VACCINES, 2023–2030 (USD MILLION)

TABLE 124 AFRICA: ANIMAL VACCINES MARKET, BYTECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 125 MAJOR PLAYERS IN THE GLOBAL ANIMAL VACCINES MARKET

TABLE 126 THE MOST ACTIVE PLAYERS IN THE GLOBAL ANIMAL VACCINES MARKET

TABLE 127 NEW PRODUCT DEVELOPMENTS/LAUNCHES/PRODUCT LICENSING AGREEMENTS

TABLE 128 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/INVESTMENTS

TABLE 129 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED

TABLE 130 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY DEVELOPMENTS

TABLE 131 ZOETIS INC.: PRODUCTS OFFERED

TABLE 132 ZOETIS INC.: KEY DEVELOPMENTS

TABLE 133 CEVA SANTÉ ANIMALE: PRODUCTS/SERVICES OFFERED

TABLE 134 CEVA SANTÉ ANIMALE: KEY DEVELOPMENTS

TABLE 135 MERCK & CO., INC.: PRODUCTS OFFERED

TABLE 136 MERCK & CO., INC.: KEY DEVELOPMENTS

TABLE 137 ELANCO ANIMAL HEALTH INCORPORATED: PRODUCTS OFFERED

TABLE 138 ELANCO ANIMAL HEALTH INCORPORATED: KEY DEVELOPMENTS

TABLE 139 VIRBAC: PRODUCTS OFFERED

TABLE 140 VIRBAC: KEY DEVELOPMENTS

TABLE 141 PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED

TABLE 142 PHIBRO ANIMAL HEALTH CORPORATION: KEY DEVELOPMENTS

TABLE 143 HIPRA: PRODUCTS OFFERED

TABLE 144 HIPRA: KEY DEVELOPMENTS

TABLE 145 BIOGÉNESIS BAGÓ S.A.: PRODUCTS OFFERED

TABLE 146 BIOGÉNESIS BAGÓ S.A.: KEY DEVELOPMENTS

TABLE 147 NEOGEN CORPORATION: PRODUCTS OFFERED

TABLE 148 NEOGEN CORPORATION: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 MARKET STRUCTURE: ANIMAL VACCINES MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: GLOBAL ANIMAL VACCINES MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINT IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL ANIMAL VACCINES MARKET

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBALANIMAL VACCINES MARKET

FIGURE 9 GLOBAL ANIMAL VACCINE MARKET, BY TYPE, 2020 & 2030 (USD MILLION)

FIGURE 10 GLOBAL ANIMAL VACCINE MARKET, BY TECHNOLOGY, 2020 & 2030 (USD MILLION)

FIGURE 11 GLOBAL: ANIMAL VACCINES MARKET, BY REGION 2020 & 2030 (USD MILLION)

FIGURE 12 GLOBAL: ANIMAL VACCINES MARKET SHARE (%), BY REGION, 2020

FIGURE 13 AMERICAS: ANIMAL VACCINES MARKET SHARE, BY REGION 2020 (%)

FIGURE 14 NORTH AMERICA: ANIMAL VACCINES MARKET SHARE, BY COUNTRY 2020 (%)

FIGURE 15 EUROPE: ANIMAL VACCINES MARKET SHARE (%), BY REGION, 2020

FIGURE 16 WESTERN EUROPE: ANIMAL VACCINES MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 17 ASIA-PACIFIC: ANIMAL VACCINES MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 18 MIDDLE EAST & AFRICA: ANIMAL VACCINES MARKET SHARE (%), BY REGION, 2020

FIGURE 19 EXPANSION: THE MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL ANIMAL VACCINES MARKET

FIGURE 20 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 21 REVENUE OF MAJOR PLAYERS, 2020

FIGURE 22 MAJOR PLAYERS R&D EXPENDITURE, 2020

FIGURE 23 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS

FIGURE 25 ZOETIS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 ZOETIS INC.: SWOT ANALYSIS

FIGURE 27 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 MERCK & CO., INC.: SWOT ANALYSIS

FIGURE 29 ELANCO ANIMAL HEALTH INCORPORATED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 ELANCO ANIMAL HEALTH INCORPORATED: SWOT ANALYSIS

FIGURE 31 VIRBAC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 VIRBAC: SWOT ANALYSIS

FIGURE 33 PHIBRO ANIMAL HEALTH CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 NEOGEN CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.